Noveome to assess ST266 to treat severe inflammatory response linked with COVID-19

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Mar 31, 2020 at 11:22 AM.

  1. #1 cafead, Mar 31, 2020 at 11:22 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,962
    Likes Received:
    3
    via Noveome Biotherapeutics has launched a new programme to assess its ST26 product candidate for the treatment of the severe inflammatory cytokine storm response associated with COVID-19, the disease resulted due to the novel coronavirus SARS-CoV-2.

    article source
     
    Quote

Reply to Thread